Related Experiment Video
Updated: Aug 19, 2025
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Precision Oncology: 2022 in Review
Ezra Rosen1, Alexander Drilon1, Debyani Chakravarty1
1Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract:
This article presents a review of the major advances and future implications in precision oncology accomplished in 2022 and centers on three primary pillars: advances in (i) rational drug design, (ii) study design, and (iii) novel biomarkers.
Insights
Precision oncology advanced in 2022 through innovations in rational drug design, study design, and novel biomarkers. These key developments are shaping the future of personalized cancer treatment strategies.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Precision oncology aims to tailor cancer treatments to individual patients.
- Significant progress in 2022 has been reviewed, focusing on key areas of advancement.
Approach:
- The review synthesizes major breakthroughs in rational drug design.
- It examines innovations in clinical trial and study design.
- Novel biomarker discovery and application are also highlighted.
Key Points:
- Advances in rational drug design are enhancing targeted therapy development.
- Innovative study designs are improving the efficiency and effectiveness of clinical trials.
- Novel biomarkers are crucial for patient stratification and treatment selection.
Conclusions:
- The integration of these pillars is accelerating the evolution of precision oncology.
- Future implications point towards more personalized and effective cancer care.
